CRISPR Therapeutics AG — Director's Dealing 2019

Nov 21, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-11-19

Reporting Person: Novak Rodger (Director, President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-19	Common Shares	M	33618	$14.43	Acquired	33618	Direct
2019-11-19	Common Shares	S	33618	$70.00	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-11-19	Stock Option (Right to Buy)	$14.43	M	33618	Disposed	2024-01-15	Common Shares (33618)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: 270,000 options to purchase common shares were granted on June 15, 2017 and originally vested in 48 equal monthly installments commencing upon the grant date. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.